MICHEL SHAMI, M.D.
Ophthalmology Physician · LUBBOCK, TX
Individual Active NPI 1780683227
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,109 | 39,467 | $7,696,488 | $2,713,864 | $2,119,896 |
| 2023 | 1,141 | 28,337 | $7,182,565 | $2,556,546 | $1,996,287 |
| 2022 | 1,119 | 13,780 | $5,763,566 | $2,036,034 | $1,577,115 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 30,180 | $34 | $27 |
| 92134 | Imaging of retina | 2,699 | $40 | $30 |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 1,905 | $147 | $117 |
| 67028 | Injection of drug into eye | 1,107 | $125 | $90 |
| J0178 | Injection, aflibercept, 1 mg | 929 | $822 | $652 |
| 92014 | Established patient complete exam of visual system | 867 | $125 | $87 |
| 92012 | Established patient problem focused exam of visual system | 511 | $89 | $62 |
| 99213 | Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 396 | $92 | $70 |
| 92004 | New patient complete exam of visual system | 262 | $148 | $107 |
| J7999 | Compounded drug, not otherwise classified | 152 | $95 | $70 |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | 56 | $161 | $124 |
| J9035 | Injection, bevacizumab, 10 mg | 23 | $61 | $45 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Ophthalmology Physician | 207W00000X | ✓ | H8830 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Ophthalmology Physician providers in Texas
- NPI 1376530071
- NPI 1437347242
- NPI 1144259656
- NPI 1912698929
- NPI 1336998475
- NPI 1205931136
- NPI 1548527047
- NPI 1336231265
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.